Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet

[unable to retrieve full-text content]

1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial  The Lancet
2. COVID-19 vaccines, and what the new coronavirus variants mean for them  ABC News
3. Immune profiling shows differences in COVID-19 and influenza pathologic pathways  News-Medical.Net
4. Covid: Antibodies last at least six months in most  BBC News
5. Understanding the drivers of transmission of SARS-CoV-2  The Lancet
6. View Full coverage on Google News

https://news.google.com/__i/rss/rd/articles/CBMiU2h0dHBzOi8vd3d3LnRoZWxhbmNldC5jb20vam91cm5hbHMvbGFuaW5mL2FydGljbGUvUElJUzE0NzMtMzA5OSgyMCkzMDk4Ny03L2Z1bGx0ZXh00gEA?oc=5

2021-02-03 23:32:31Z
52781342059721

Bagikan Berita Ini